Pharmaceutical Excipients Market Size & Growth Forecast 2027–2036, By Segments (Product, Functionality, Formulation), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Pharmaceutical Excipients Market size was valued at USD 11.09 Billion in 2026 and is anticipated to grow at 8.48% CAGR from 2027 to 2036, crossing USD 25.03 Billion by 2036. The industry revenue for 2027 is estimated at USD 11.89 Billion.

• Base Year Value (2026): USD 11.09 Billion
• CAGR (2027-2036): 8.48%
• Forecast Year Value (2036): USD 25.03 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Pharmaceutical Excipients Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held 45.26% in 2025, supported by its established pharmaceutical manufacturing base, advanced drug development, sophisticated infrastructure, and demand for high-quality formulation ingredients.
  • Asia Pacific is growing fastest through expanding pharmaceutical capacity, healthcare demand, domestic drug production, generic medicines, and investments in formulation infrastructure.

• Segment Momentum:

  • Organic chemicals accounted for 51.3% of the market in 2025, driven by their compatibility with active pharmaceutical ingredients and their ability to improve stability, bioavailability, and manufacturability across drug formulations.
  • Parenteral formulations are growing fastest due to expanding development of biologics, injectable medicines, and specialty therapeutics that require highly specialized excipients for sterility, stability, and product safety.

• Market Expansion Drivers:

  • Growing demand for generic and branded pharmaceuticals driving excipients consumption
  • Expiration of major drug patents increasing demand for formulation support ingredients
  • Advancements in functional and specialty excipients improving drug delivery performance

• Leading Market Participants:

  Major players in the pharmaceutical excipients market include BASF SE (Germany), Evonik Industries AG (Germany), Ashland Inc. (United States), Croda International Plc (United Kingdom), Merck KGaA (Germany), Archer Daniels Midland Company (United States), Kerry Group plc (Ireland), Associated British Foods plc (United Kingdom), Roquette Frères S.A. (France), DuPont de Nemours, Inc. (United States)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 11.09 Billion
  • 2027 Estimated Market Size: USD 11.89 Billion
  • Projected Market Size: USD 25.03 Billion by 2036
  • Growth Forecasts: 8.48% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Organic Chemicals (Product) | Binder (Functionality) | Oral (Formulation)
  • Emerging Opportunity Segment: Inorganic Chemicals (Product) | Filler & Diluent (Functionality) | Parenteral (Formulation)

Market Growth Drivers and Industry Trends

Growing demand for generic and branded pharmaceuticals driving excipients consumption

Rising pharmaceutical production across generic and innovative drug segments is increasing the need for high-quality formulation ingredients, and the pharmaceutical excipients market growth is driven by expanding excipient requirements in drug manufacturing. Excipients play an essential role in improving drug stability, absorption, appearance, and manufacturability across various dosage forms. As pharmaceutical companies develop a broader range of therapies and increase production volumes, demand is growing for reliable excipient solutions that support consistent formulation performance.

Expiration of major drug patents increasing demand for formulation support ingredients

The increasing availability of off-patent medicines is encouraging generic manufacturers to expand production, which will strengthen the pharmaceutical excipients market demand. Generic drug development requires precise formulation strategies to replicate therapeutic performance while maintaining quality and regulatory compliance. Excipients support these processes by enabling appropriate drug release profiles, improving manufacturing efficiency, and helping formulators adapt active ingredients into commercially viable dosage forms as patent exclusivity periods end.

Advancements in functional and specialty excipients improving drug delivery performance

Innovation in excipient technologies is enhancing the capabilities of modern pharmaceutical formulations, supporting growth in the pharmaceutical excipients market. Functional excipients are being developed to improve targeted delivery, controlled release, bioavailability, and patient convenience across complex therapeutic applications. As drug developers increasingly focus on advanced delivery mechanisms and specialized formulations, demand is rising for excipients that provide greater formulation flexibility and improved treatment outcomes.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Growing demand for generic and branded pharmaceuticals driving excipients consumption	2%	High	North America, Asia Pacific	High	Near Term
Expiration of major drug patents increasing demand for formulation support ingredients	1.8%	High	Europe, North America	High	Mid Term
Advancements in functional and specialty excipients improving drug delivery performance	1.7%	Moderate	Global	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

In the pharmaceutical excipients market, North America held the largest share of 45.26% in 2026, supported by its established pharmaceutical manufacturing base, advanced drug development capabilities, and strong demand for high-quality formulation ingredients. The region benefits from sophisticated production infrastructure and stringent quality requirements that encourage pharmaceutical manufacturers to adopt reliable excipients for improving drug stability, bioavailability, and overall formulation performance. Continued investment in innovative therapies and complex drug formulations is also supporting demand for specialized excipients across the pharmaceutical sector.

Asia Pacific is expected to record the fastest growth, driven by expanding pharmaceutical manufacturing capacity, increasing healthcare demand, and the development of domestic drug production capabilities. Growing investments in pharmaceutical infrastructure and formulation facilities are creating opportunities for excipient suppliers, while rising demand for generic medicines and advanced drug delivery systems is broadening the need for diverse formulation ingredients. Regulatory modernization and increasing adoption of quality-focused manufacturing practices are further supporting the regional market's expansion.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Product Segment Analysis: Organic Chemicals (Largest Segment) vs Inorganic Chemicals (Fastest-Growing Segment)

Holding the largest share of the pharmaceutical excipients market, the organic chemicals segment accounted for 51.3% in 2026. The segment's dominance is supported by the widespread use of cellulose derivatives, carbohydrates, and other organic excipients across a broad range of pharmaceutical formulations. These materials are valued for their excellent compatibility with active pharmaceutical ingredients, favorable safety profiles, and versatility in improving product stability, bioavailability, and manufacturability. Growing pharmaceutical production and continuous innovation in drug formulations continue to reinforce demand for organic chemical excipients.

The inorganic chemicals segment is expected to witness the fastest growth due to increasing demand for excipients that enhance formulation stability, improve processing efficiency, and support specialized drug delivery systems. Inorganic excipients are gaining wider acceptance in advanced pharmaceutical manufacturing because of their functional properties and suitability for diverse dosage forms. Rising development of complex pharmaceutical products and continuous improvements in formulation technologies are expected to accelerate growth within this segment.

Functionality Segment Analysis: Binder (Largest Segment) vs Filler & Diluent (Fastest-Growing Segment)

The binder segment captured 20.57% of the market share in 2026, making it the leading functionality segment. Binders play a critical role in maintaining tablet integrity by ensuring strong cohesion among formulation ingredients while improving mechanical strength and manufacturing efficiency. Their extensive use across solid dosage formulations, combined with increasing pharmaceutical production and demand for high-quality oral medications, has sustained the segment's dominant position.

The pharmaceutical excipients market is anticipated to register the fastest growth in the filler & diluent segment as pharmaceutical manufacturers increasingly develop formulations requiring improved dosage uniformity and optimized processing characteristics. Fillers and diluents are essential for achieving consistent tablet size, weight, and stability while supporting efficient large-scale manufacturing. Growing production of generic medicines, expanding pharmaceutical pipelines, and continuous innovation in formulation technologies are expected to strengthen demand for these excipients.

Formulation Segment Analysis: Oral (Largest Segment) vs Parenteral (Fastest-Growing Segment)

The pharmaceutical excipients market was led by the oral formulation segment, which held the largest share in 2026. Oral formulations remain the preferred dosage form because they offer convenient administration, high patient acceptance, cost-effective manufacturing, and well-established production processes. Tablets, capsules, and other oral dosage forms continue to account for substantial pharmaceutical demand, supporting consistent consumption of excipients designed for solid oral formulations.

The parenteral formulation segment is expected to experience the fastest growth as the development of biologics, specialty therapeutics, and injectable medicines continues to expand. Parenteral formulations require highly specialized excipients that ensure sterility, stability, and compatibility while maintaining product safety and effectiveness. Increasing demand for injectable therapies, advanced biologics, and hospital-administered medications is expected to accelerate growth across this formulation segment.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Organic chemicals, Inorganic chemicals, Other products
Formulation	Oral, Liquid, Parenteral, Topical, Other formulations
Functionality	Binder, Suspension and viscosity agents, Glidants, Preservatives, Filler & diluent, Lubricant, Emulsifier, Disintegrant, Other functionalities

Competitive Landscape and Market Positioning

Leading companies in the pharmaceutical excipients market:

1. BASF SE (Germany)
2. Evonik Industries AG (Germany)
3. Ashland, Inc. (United States)
4. Croda International Plc (United Kingdom)
5. Merck KGaA (Germany)
6. Archer Daniels Midland Company (United States)
7. Kerry Group plc (Ireland)
8. Associated British Foods plc (United Kingdom)
9. Roquette Frères S.A. (France)
10. DuPont de Nemours, Inc. (United States)

Competitive positioning in the pharmaceutical excipients market is increasingly shaped by the ability to support more complex drug formulations while meeting evolving regulatory and quality expectations across global manufacturing networks. Suppliers are moving beyond commodity ingredient offerings by expanding formulation expertise, improving material consistency, and providing technical support that helps pharmaceutical manufacturers accelerate product development and scale production with greater confidence. As biologics, specialized delivery systems, and patient-centric dosage formats become more prominent, competition is shifting toward excipients designed to enhance stability, bioavailability, and manufacturing performance. At the same time, differentiation is emerging through secure raw material sourcing, comprehensive documentation, and flexible production capabilities that enable suppliers to address diverse compliance requirements across multiple end-use applications.

Industry Development/News

Company Name	Date	Key Development
Ashland	Jun-26	Ashland initiated construction on a major tablet coatings manufacturing facility in Ambernath, India, marking its first South Asian coatings plant to supply the regional pharmaceutical and nutraceutical sectors with its Aquarius brand excipient systems.
Ingredion Incorporated	May-26	Ingredion established a strategic partnership with Sanstar Limited through a planned Rs 198.3 crore preferential equity allotment to form a joint venture in India focused on manufacturing high-value specialty pharmaceutical excipients.
Safic-Alcan	May-26	Safic-Alcan expanded its operational footprint in Asia by acquiring a majority stake in SA Ingredients, a move that directly secures and enhances its regional distribution networks for active pharmaceutical ingredients and excipients.
Clariant	Mar-26	Clariant completed an expansion at its Clear Lake, Texas facility to launch its initial US-based manufacturing operations for GMP-compliant, pharmaceutical-grade polyethylene glycol excipients, securing supply chains across North America and Latin America.
DFE Pharma	Feb-26	DFE Pharma established a dedicated Continuous Manufacturing platform in Hyderabad, providing localized infrastructure to accelerate formulation development, process optimization, and lifecycle management for drug developers transitioning to continuous processing techniques.
Sigachi Industries	Aug-25	Sigachi Industries launched a manufacturing expansion project in Dahej, Gujarat, adding 12,000 MTPA of microcrystalline cellulose production capacity to scale its core pharmaceutical excipient operations and meet rising industry demand.
Roquette	May-25	Roquette completed the strategic acquisition of IFF Pharma Solutions, significantly broadening its pharmaceutical excipients portfolio and strengthening its competitive footprint across the global health and nutrition ingredients sectors.
Shin-Etsu Chemical Co., Ltd.	Apr-25	Shin-Etsu Chemical committed capital investments across two of its primary operating locations to scale production capabilities and reinforce its global competitive positioning within the pharmaceutical cellulose excipient sector.
Ashland	Jun-23	Ashland commercialized Polyplasdone Plus, an innovative co-processed direct compression superdisintegrant integrating a glidant and lubricant, which optimizes powder flow and eliminates two stages from the traditional pharmaceutical manufacturing process.
BASF Pharma Solutions	Jan-22	The U.S. FDA accepted BASF's Soluplus excipient into the Pilot Program for the Review of Innovation and Modernization of Excipients, creating a formal pathway to reduce regulatory hurdles for novel excipient integration in modern drug development.